In a 73‑year‑old patient with coronary artery disease status post triple coronary artery bypass grafting (left internal mammary artery to left anterior descending artery, saphenous‑vein grafts to posterior descending artery and diagonal branch 1) who is asymptomatic and has no bleeding, should low‑dose aspirin 81 mg be continued indefinitely according to guidelines?

Yes, Continue Aspirin 81 mg Daily Indefinitely

Your 73-year-old patient with prior CABG should continue aspirin 81 mg daily indefinitely as lifelong antiplatelet therapy, regardless of age, as long as he remains asymptomatic without bleeding complications. 1

Guideline-Based Recommendation

Class I Indication for Indefinite Aspirin After CABG

• Aspirin should be continued indefinitely after coronary revascularization procedures including CABG (Level of Evidence: A). 1
• The 2011 ACC/AHA/SCAI PCI guidelines explicitly state that "after PCI, use of aspirin should be continued indefinitely" and this applies equally to post-CABG patients. 1
• The 2014 AHA/ACC NSTE-ACS guidelines reinforce that "aspirin should be continued indefinitely" with a maintenance dose of 81 mg daily. 1

Optimal Dosing: 81 mg Daily is Preferred

• It is reasonable to use aspirin 81 mg per day in preference to higher maintenance doses (Class IIa, Level of Evidence: B). 1
• The lower dose of 81 mg provides equivalent cardiovascular protection while minimizing bleeding risk compared to higher doses (162-325 mg). 1

Age is Not a Contraindication

• There is no upper age limit for continuing aspirin in patients with established coronary artery disease who have undergone revascularization. 1
• The recent 2022 USPSTF recommendation against initiating aspirin in adults ≥60 years applies only to primary prevention (patients without known CVD), not to secondary prevention in patients with established CAD status post CABG. 2
• Your patient has established CAD with prior CABG—this is secondary prevention, where aspirin remains a Class I recommendation regardless of age. 1, 3

When to Consider Discontinuation

Only discontinue aspirin if:

• Active bleeding occurs or the patient develops a contraindication (history of intracranial hemorrhage, severe bleeding disorder). 1
• The risk of morbidity from bleeding clearly outweighs anticipated cardiovascular benefit—this requires documented high bleeding risk, not simply advanced age alone. 1
• Patient develops documented aspirin hypersensitivity (true allergy, not intolerance), in which case clopidogrel 75 mg daily becomes the alternative. 3, 4

Common Pitfalls to Avoid

• Do not discontinue aspirin based solely on age. The 73-year-old age is irrelevant in the context of established CAD with prior CABG. 1
• Do not confuse primary prevention guidelines with secondary prevention. The USPSTF 2022 recommendation against aspirin initiation in older adults applies only to those without known CVD. 2
• Do not use higher doses without indication. The 81 mg dose provides optimal benefit-to-risk ratio for long-term secondary prevention. 1
• Ensure the patient is not on dual antiplatelet therapy (DAPT) indefinitely without indication. Post-CABG patients typically require only aspirin monotherapy unless they have had a recent ACS or PCI with stent placement. 1

Additional Considerations for Post-CABG Patients

• Aspirin improves saphenous vein graft patency when continued long-term, which is particularly relevant for your patient with SVG grafts to PDA and D1. 1, 5
• Monitor for gastrointestinal symptoms but do not discontinue aspirin preemptively. Consider proton pump inhibitor (PPI) co-therapy if the patient has risk factors for GI bleeding (history of ulcers, concurrent NSAID use, age >60 with other risk factors). 1
• Confirm medication adherence as aspirin discontinuation is associated with increased cardiovascular events in secondary prevention populations. 6, 7